产品
编 号：F749685
分子式：C29H22Cl2N2O5
分子量：549.4
分子式：C29H22Cl2N2O5
分子量：549.4
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2181834-03-5
产品详情
生物活性：
HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC50 values of 1.37 and 1.55 nM by time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. HEC96719 significantly improves non-alcoholic steatohepatitis (NASH) and liver fibrosis with favorable tissue distribution in liver and intestine. HEC96719 can be used for the research of non-alcoholic steatohepatitis.
体内研究：
HEC96719 (0.5，1.5 和 5 mg/kg；口服，每天 1 次，共 14 天) 通过测定增加成纤维细胞生长因子 15 (FGF15)的水平证明激活了 FXR.HEC96719 (5 mg/kg；口服，1 次) 增加肝胆盐输出泵 (BSEP) 的水平和回肠中 FGF15 的水平。HEC96719 (0.1, 0.3 和 1 mg/kg；口服，每日 1 次，持续 6 周) 显著改善非酒精性脂肪性肝炎 (NASH) 症状。HEC96719 (0.1，0.3 和 1 mg/kg；口服，每日 1 次，持续 4 周) 对改善肝纤维化有效果，且优于奥贝胆酸 (OCA)。Animal Model:Male ob/ob nonalcoholic steatohepatitis (NASH) mouse models
Dosage:0.1, 0.3 and 1 mg/kg
Administration:Oral administration; 0.1, 0.3 and 1 mg/kg, once daily for 6 weeks
Result:Decreased levels of serum alanine aminotransferase (ALT) and liver triglyceride (TG), dose-dependently increased NASH activity and reduced NASH activity score.
Animal Model:Male C57BL/6 liver fibrosis mouse models
Dosage:0.1, 0.3 and 1 mg/kg
Administration:Oral administration; 0.1, 0.3 and 1 mg/kg, once daily for 4 weeks
Result:Decreased levels of serum ALT and TBIL, and reduced fibrosis area.
HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC50 values of 1.37 and 1.55 nM by time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. HEC96719 significantly improves non-alcoholic steatohepatitis (NASH) and liver fibrosis with favorable tissue distribution in liver and intestine. HEC96719 can be used for the research of non-alcoholic steatohepatitis.
体内研究：
HEC96719 (0.5，1.5 和 5 mg/kg；口服，每天 1 次，共 14 天) 通过测定增加成纤维细胞生长因子 15 (FGF15)的水平证明激活了 FXR.HEC96719 (5 mg/kg；口服，1 次) 增加肝胆盐输出泵 (BSEP) 的水平和回肠中 FGF15 的水平。HEC96719 (0.1, 0.3 和 1 mg/kg；口服，每日 1 次，持续 6 周) 显著改善非酒精性脂肪性肝炎 (NASH) 症状。HEC96719 (0.1，0.3 和 1 mg/kg；口服，每日 1 次，持续 4 周) 对改善肝纤维化有效果，且优于奥贝胆酸 (OCA)。Animal Model:Male ob/ob nonalcoholic steatohepatitis (NASH) mouse models
Dosage:0.1, 0.3 and 1 mg/kg
Administration:Oral administration; 0.1, 0.3 and 1 mg/kg, once daily for 6 weeks
Result:Decreased levels of serum alanine aminotransferase (ALT) and liver triglyceride (TG), dose-dependently increased NASH activity and reduced NASH activity score.
Animal Model:Male C57BL/6 liver fibrosis mouse models
Dosage:0.1, 0.3 and 1 mg/kg
Administration:Oral administration; 0.1, 0.3 and 1 mg/kg, once daily for 4 weeks
Result:Decreased levels of serum ALT and TBIL, and reduced fibrosis area.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备